Oncology and Hematology - Global Oncology Academy

65-80 of 152

Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
MinuteCE®
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Scott Kopetz, MD, PhD; Cathy Eng, MD, FACP
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
MinuteCE®
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Scott Kopetz, MD, PhD; Cathy Eng, MD, FACP
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
MinuteCE®
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Scott Kopetz, MD, PhD; Cathy Eng, MD, FACP
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
CME/CE
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Kevin Kalinsky MD, MS; Komal Jhaveri, MD, FACP
0.50 credits
- Kevin Kalinsky MD, MS
- Komal Jhaveri, MD, FACP
0.50 credits
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
MinuteCE®
Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
MinuteCE®
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
MinuteCE®
Case Consult: Adverse Effect Monitoring, Management, and Mitigation During Targeted Therapy for BRAF-Mutant mCRC
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
From Guidelines to Practice: First-Line Treatment Choices in mCRC
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
Fortunato Ciardiello, MD, PhD; Jenny Seligmann, MBChB, PhD
1.00 program credit
- Fortunato Ciardiello, MD, PhD
- Jenny Seligmann, MBChB, PhD
1.00 program credit
MinuteCE®
Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
Jenny Seligmann, MBChB, PhD; Fortunato Ciardiello, MD, PhD
1.00 credit 10 episodes
- Jenny Seligmann, MBChB, PhD
- Fortunato Ciardiello, MD, PhD
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 credit 10 episodes
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
CME/CE
Maximizing Myeloma Outcomes With GPRC5D-Directed Therapy: Practical Expert Case Studies and Best Practices
0.25 credits
0.25 credits
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Aparna R. Parikh, MD
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
MinuteCE®
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Aparna R. Parikh, MD
1.25 program credits
- Aparna R. Parikh, MD
1.25 program credits
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
Sara Lonardi, MD; Aparna R. Parikh, MD
1.25 credits 10 episodes
- Sara Lonardi, MD
- Aparna R. Parikh, MD
- Alan Venook, MD
1.25 credits 10 episodes
Expert Viewpoint: Optimizing Breast Cancer Treatment
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
William J. Gradishar, MD; Erica L. Mayer, MD, MPH
1.50 program credits
- William J. Gradishar, MD
- Erica L. Mayer, MD, MPH
- Peter Schmid, FRCP, MD, PhD
1.50 program credits
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Erica L. Mayer, MD, MPH
1.50 program credits
- Erica L. Mayer, MD, MPH
1.50 program credits

5/10